Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
AssigneeSignpath Pharma, Inc.
InventorsLawrence Helson, George M. Shopp, Annie Bouchard, Muhammed Majeed
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.
Claims7
A method for preventing or treating one or more cardiac channelopathies, irregularities or alterations in cardiac patterns, IKr channel inhibition or QT prolongation, in a human or animal subject in need thereof caused by an active agent or drug, wherein the active agent or drug are used to treat a disease in a human or animal subject comprising the steps of:
- administering to the human or animal subject a composition consisting essentially of:
- an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or cardiac channelopathies, irregularities or alterations in cardiac patterns, IKr channel inhibition, or QT prolongation caused by the active agent or drug;
- an effective amount of the active agent or drug sufficient to treat the disease, wherein the orally provided lysophosphatidylglycerol reduces or eliminates the at least one cardiac channelopathies, irregularities or alterations in cardiac patterns, IKr channel inhibition or QT prolongation;
- and
- one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.
Dependencies are inferred from the claim text.